On Wednesday, Shares of Voya Financial Inc (NYSE:VOYA), lost -1.20% to $38.82.
Voya Financial, declared that Karen Eisenbach has joined the company as chief marketing officer for its Retirement business. In this role she will oversee the marketing strategy for Voya’s institutional and retail retirement segments while partnering closely with Corporate Marketing to drive greater awareness and engagement with distribution partners, plan sponsors and retirement plan participants. Eisenbach will be based in Voya’s Windsor office and report to CEO of Retirement Charles P. Nelson.
Eisenbach brings extensive experience in marketing, sales, product administration and planned planning to Voya, together with a strong background in the retirement industry. Most recently, she was executive director of Retirement Marketing for J.P. Morgan Asset Administration where she assisted develop and launch a retirement offering for small- and mid-sized plan sponsors. Eisenbach also managed her own consulting business and held preceding leadership positions with Nationwide Financial and National City Bank.
“As we look to grow and find new ways to reach customers, especially through digital and data-driven initiatives, strong marketing leadership will be critical for our success,” said Nelson. “With her depth of experience in private and public sector retirement markets, knowledge of different product lines and distribution channels, and successful track record managing high-performing teams, I’m confident that Karen will make noteworthycontributions as a part of our team. I look forward to working together as we assist more people plan, invest and protect their savings for retirement.”
Voya Financial, Inc. operates as a retirement, investment, and insurance company in the United States. The company has five segments: Retirement, Annuities, Investment Administration, Individual Life, and Employee Benefits.
Shares of Diamond Offshore Drilling Inc (NYSE:DO), inclined 0.88% to $19.56, during its last trading session.
Loews Corporation, will report third quarter 2015 financial results on Monday, November 2, 2015. A conference call for analysts and investors will start at 11:00 a.m. EST and will be hosted by the Company’s chief executive officer, James S. Tisch, and chief financial officer, David B. Edelson.
Diamond Offshore Drilling, Inc. provides contract drilling services to the energy industry worldwide. The company provides services in floater market, such as ultra-deepwater, deepwater, and mid-water; and non-floater or jack-up market.
Finally, Shire PLC (ADR) (NASDAQ:SHPG), ended its last trade with 1.85% gain, and closed at $200.50.
Shire plc, declared that the United States Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of CINRYZE® (C1 esterase inhibitor [human]) for intravenous administration in subjects with Antibody Mediated Rejection (AMR) in renal transplant recipients. CINRYZE is being studied as an adjunct treatment to Donor Specific Antibodies (DSA) reduction therapy in kidney transplant patients with acute AMR.
“There are presently no approved therapies for Antibody Mediated Rejection, a life-threatening and debilitating condition which can manifest in patients receiving kidney transplants,” said Philip J. Vickers, Ph.D., Head of Research and Development at Shire. “The Fast Track designation represents an understanding of the noteworthyunmet medical need for this condition. Shire looks forward to working closely with the FDA as we continue to study CINRYZE as a potential treatment option for these patients.”
Shire is planning a Phase 3 multi-center, multi-national, randomized, double-blind, placebo-controlled study (SHP616-302) to evaluate the efficacy of CINRYZE (intravenous administration) as an adjunct to DSA reduction therapy (plasmapheresis, plasma exchange, and/or immune adsorption treatments and IVIG) for the treatment of acute AMR in kidney transplant recipients. The trial will be conducted in the United States, Europe and Canada and the study will open for enrollment by the end of October 2015.
Shire plc, a biopharmaceutical company, together with its auxiliaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), counting VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
